biostudies-literatureEpstein-Peterson ZDNCI NIH HHS5654-5662https://www.ebi.ac.uk/biostudies/studies/S-EPMC12848353biostudies-literatureUnknown9(21)<h4>Abstract</h4>The treatment patterns and clinical outcomes for patients experiencing progression of disease (POD) following CD19-directed chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory (R/R) mantle cell lymphoma (MCL) are undefined. We identified all patients who received CD19-directed CAR T-cell therapy for R/R MCL therapy across 15 international centers, and studied those experiencing POD post-CAR T-cell therapy in detail. We extracted clinical/treatment/pathologic variables, and associated these features with survival outcomes. In total, 384 patients received CAR T-cell therapy, and 135 (35%) experienced POD. POD occurred at a median of 6 months following CAR T-cell therapy infusion, and most (64%) patients with POD had complete response as best response toBlood advancesTreatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis.PMC12848353P30 CA008748Rhodes JChong EAShouval RLionel ACDrill EIp AMunoz JLVaron BKarmali RMerryman RWKamdar MKZelenetz ADFrank MJSawalha YRiedell PAvan Besien HJacobson CANavalekar RWang YYamshon SPalomba MLJain PBeyar-Katz OSharma SMaddocks KJBrooks TRSauter CSEpstein-Peterson ZDMatasar MJShukla NSalles GDela Cruz JRyan CEAtallah-Yunes SAChong ERTherwhanger DMcLoughlin DJoseph AKumar AIqbal MfalseTreatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis.<h4>Abstract</h4>The treatment patterns and clinical outcomes for patients experiencing progression of disease (POD) following CD19-directed chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory (R/R) mantle cell lymphoma (MCL) are undefined. We identified all patients who received CD19-directed CAR T-cell therapy for R/R MCL therapy across 15 international centers, and studied those experiencing POD post-CAR T-cell therapy in detail. We extracted clinical/treatment/pathologic variables, and associated these features with survival outcomes. In total, 384 patients received CAR T-cell therapy, and 135 (35%) experienced POD. POD occurred at a median of 6 months following CAR T-cell therapy infusion, and most (64%) patients with POD had complete response as best response to2025-01-01T00:00:00Z2025 Nov2026-06-14T06:07:28.451Z2026-06-14T03:16:44.283ZS-EPMC128483534076326910.1182/bloodadvances.2025016315